AustraliaDaily Briefs

Daily Brief Australia: Mayne Pharma, Iron Ore, Stanmore Coal and more

In today’s briefing:

  • Mayne Pharma’s Merger with Cosette Pharmaceuticals: Navigating FDA Concerns, Shareholder Approval, and Market Reactions
  • [IO Technical 2025/20] Bullish Momentum Builds
  • Quiddity Leaderboard ASX Jun25: LONGs up 6% Vs SHORTs; Strong Alpha; Reference Period Ending Soon


Mayne Pharma’s Merger with Cosette Pharmaceuticals: Navigating FDA Concerns, Shareholder Approval, and Market Reactions

By Special Situation Investments

  • Mayne Pharma’s acquisition by Cosette Pharmaceuticals at A$7.40/share faces a 14% spread, with closing expected in 1.5 months.
  • The FDA issued an Untitled Letter to Mayne Pharma about Nexstellis promotional materials, but it is unlikely to trigger a material adverse effect.
  • Shareholder approval for the merger appears likely, with key stakeholders supporting the deal and a vote scheduled for June 18.

[IO Technical 2025/20] Bullish Momentum Builds

By Pranay Yadav

  • Iron ore futures surged to a six-week high as U.S.-China trade tensions eased, with both nations agreeing to sharply reduce tariffs for 90 days, boosting market sentiment and commodity demand. 
  • Underlying demand remains weak, with China’s steel consumption pressured by a cooling property sector and ongoing structural shifts across its broader economic landscape. 
  • On the technical front, the outlook is turning increasingly bullish as prices are holding above key moving averages. 

Quiddity Leaderboard ASX Jun25: LONGs up 6% Vs SHORTs; Strong Alpha; Reference Period Ending Soon

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the potential index changes for ASX 200, 100, 50, and 20 in the run-up to the June 2025 index rebal event.
  • We expect one change for ASX 20, one change for ASX 50, two changes for ASX 100, and one change for ASX 200. 
  • The official index changes will be announced after the close on Friday 6th June 2025.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars